Home Tags RHAR, PRES

Tag: RHAR, PRES

ACR: Cycling JAK Inhibitors Feasible for Difficult-to-Treat RA

ACR: Incidence of COVID-19 Low in Patients With Rheumatic Disease

Upadacitinib Beats Methotrexate in Early Rheumatoid Arthritis

Risk for Adverse Events Up With Low-Dose Methotrexate

Factors Examined for Time to First Rx for Biologic DMARD in...

Combo Tx May Improve Disease Control for Some in Early RA

Filgotinib Bests Placebo in Tx of Refractory Rheumatoid Arthritis

Tofacitinib Benefits Sustained for Two Years in Patients With RA

© 1999 - 2021 e-Healthcare Solutions